Last reviewed · How we verify
CBT-001 single dose
CBT-001 is a small molecule that targets the CD47/SIRPα axis.
CBT-001 is a small molecule that targets the CD47/SIRPα axis. Used for Metastatic solid tumors.
At a glance
| Generic name | CBT-001 single dose |
|---|---|
| Sponsor | Cloudbreak Therapeutics, LLC |
| Drug class | CD47/SIRPα axis inhibitor |
| Target | CD47 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CBT-001 works by blocking the interaction between CD47 and SIRPα on the surface of immune cells, thereby enhancing phagocytosis of tumor cells. This mechanism is thought to be involved in the anti-tumor activity of CBT-001.
Approved indications
- Metastatic solid tumors
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CBT-001 single dose CI brief — competitive landscape report
- CBT-001 single dose updates RSS · CI watch RSS
- Cloudbreak Therapeutics, LLC portfolio CI